AstraZeneca could face limited fallout from Chinese tax probe
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
Hong Kong shareholders have foiled plans by Fosun Pharma to take its biologics subsidiary off the stock market at half the IPO price Key Takeaways: Fosun Pharma has pledged to…
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
A family of biotech contracting companies in Wuxi has begun selling offshore assets under pressure from Western governments worried about national security. And a family feud in Shanghai has left a $1 billion luxury villa complex in limbo.
BeiGene heads for profit milestone after hemorrhaging cash
With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
TCMTech fuses old with the new by mixing AI and Chinese medicine
China’s biggest provider of AI-empowered healthcare services using traditional Chinese medicine has filed for a Hong Kong IPO Key Takeaways: TCMTech has filed to list in Hong Kong, reporting its…
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
The veterinary vaccine producer raised a modest $6.9 million in its New York listing by selling just 3% of its shares, as it diversifies into the household pets market Key…
WuXi Biologics sells vaccine plant as new U.S. law looms
The Chinese drug services giant built an Irish factory to produce vaccines for Merck, but has now opted to sell the plant to the U.S.-based multinational for $500 million Key…